Vitamin D modulates peripheral immunity in patients with Behçet's disease

Clinical and Experimental Rheumatology

Volumn 28, Issue 4 SUPPL. 60, 2010, Pages

  Hamzaoui, Kamel ^a   Dhifallah, Imene Ben ^a   Karray, Emna ^a,b   Sassi, Fayçal Haj ^a   Hamzaoui, Agnes ^a,c  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b MONGI SLIM HOSPITAL   (Tunisia)

^c ABDERRAHMAN MAMI HOSPITAL   (Tunisia)

Author keywords

Beh et's disease; Inflammatory mediators; Th1; Th17; Vitamin D

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; VITAMIN D;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; ARTHRITIS, RHEUMATOID; BEHCET SYNDROME; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNITY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; VITAMIN D; YOUNG ADULT;

EID: 78049353553     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. YAZICI H, FRESKO I, YURDAKUL S: Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007, 3: 148-55
2. YAZICI H, FRESKO I, TUNÇ R, MELIKOGLU M: Behçet's syndrome: pathogenesis, clinical manifestations and treatment. In: BALL GV, BRIDGES SL (Eds.): Vasculitis. New York, US: Oxford University Press, 2002. pp. 406-32.
3. MEGE JL, DILSEN N, SANGUEDOLCE V et al.: Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.
4. HAMZAOUI K, HAMZAOUI A, GUEMIRA F, HAMZA M, AYED K: Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-10.
5. LEVENTIS P, PATEL S: Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology (Oxford). 2008; 47: 1617-21.
6. SWAMY N, ROY R: Affinity labeling of rat serum vitamin D binding protein. Arch Biochem Biophys 1996; 333: 139-44.
7. GUHA C, OSAWA M, WERNER PA, GALBRAITH RM, PADDOCK GV: Regulation of human Gc (vitamin D-binding) protein levels: hormonal and cytokine control of gene expression in vitro. Hepatology 1995; 21: 1675-81.
8. CANTORNA MT, MAHON BD: Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med 2004; 229: 1136-42.
9. MUNGER KL, LEVIN LI, HOLLIS BW, HOWARD NS, ASCHERIO A: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Am Med Assoc 2006; 296: 2832-8.
10. CUTOLO M, OTSA K, LEHTME R et al.: Circannual vitamin D serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 2006; 24: 702-4.
11. INTERNATIONAL STUDY GROUP FOR BEHÇET'S DISEASE: Criteria for the diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
12. BHAKTA BB, BRENNAN P, JAMES TE, CHAMBERLAIN MA, NOBLE BA, SILMAN AJ: Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology 1999; 38: 728-33.
13. LAWTON G, BHAKTA BB, CHAMBERLAIN MA, TENNANT A: The Behçet's disease activity index. Rheumatology 2004; 43: 73-8.
14. HOUMAN MH, NEFFATI H, BRAHAM A et al.: Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol 2007; 25 (Suppl. 45): S58-64.
15. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. POSER CM, PATY DW, SCHEINBERG L et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann. Neurol 1983; 13: 2227-310.
17. HAMZAOUI K, HOUMAN H, HAMZAOUI A: Regulatory T cells in cerebrospinal fluid from Behçet's disease with neurological manifestations. J Neuroimmunol 2007; 187: 201-4.
18. + regulatory T cells in patients with Behçet's disease. Clin Exp Rheumatol 2006; 24 (Suppl. 42): S71-8.
19. HOLLICK MF: Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
20. HOLLICK MF: High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353-73.
21. CANTORNA MT, ZHU Y, FROICU M, WITTKE A: Vitamin D status, 1, 25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80: 1717-20.
22. HAREL M, SHOENFELD Y: Predicting and preventing autoimmunity, myth or reality? Ann NY Acad Sci 2006; 1069: 322-45.
23. DO JE, KWON SY, PARK S, LEE ES: Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behçet's disease. Rheumatology (Oxford) 2008; 47: 840-8.
24. CUTILLAS-MARCO E, MORALES-SUÁREZ-VARELA MM, MARQUINA-VILA A, GRANT WB: Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010; 19: 810-4.
25. CUTOLO M: Vitamin D and autoimmune rheumatic diseases, Rheumatology (Oxford) 2009; 48: 210-2.
26. ARNSON Y, AMITAL H. AND SHOENFELD Y: Vitamin D and autoimmunity: new aetiological and therapeutic considerations, Ann Rheum Dis 2007; 66: 1137-42.
27. SEARING DA, ZHANG Y, MURPHY JR, HAUK PJ, GOLEVA E, LEUNG DY: Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 2010; 125: 995-1000.
28. YU S, CANTORNA MT: The vitamin D receptor is required for iNKT cell development. Proc Natl Acad Sci USA 2008; 105: 5207-12.
29. CANNELL JJ, HOLLIS BW, ZASLOFF M, HEANEY RP: Diagnosis and treatment of vitamin D deficiency, Expert Opin Pharmacother 2008; 9: 107-18.
30. CIGOLlNI M, IAGULLI MP, MICONI V, GALIOTTO M, LOMBARDI S, TARGHER G: Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 2006; 29: 722-4.
31. PAPPA HM, GRAND RJ, GORDON CM: Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006; 12: 1162-74.
32. CORREALE J, YSRRAELIT MC, GAITÁN MI: Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009; 132: 1146-60.
33. SMOLDERS J, DAMOISEAUX J, MENHEERE P, HUPPERTS R: Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194: 7-17.
34. KAMEN D, ARANOW C: Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20: 532-7.
35. MAHON BD, WITTKE A, WEAVER V, CANTORNA MT: The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem. 2003; 89: 922-32.
36. VAN ETTEN E, MATHIEU C: Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
37. BAEKE F, KORF H, OVERBERGH L et al.: Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D(3) in the immune system. J Steroid Biochem Mol Biol 2010; 121: 221-7.
38. MARUOTTI N, CANTATORE FP: Vitamin D and the immune system. J Rheumatol 2010; 37: 491-5.
39. DIRESKENELI H, SARUHAN-DIRESKENELI G: The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 2003; 21 (Suppl. 30): S44-8.
40. DALGHOUS AM, FREYSDOTTIR J, FORTUNE F: Expression of cytokines, chemokines and chemokine receptors in oral ulcers of patients with Behçet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 2006; 35: 472-5.
41. KAHAN A, HAMZAOUI K, AYED K: Abnormalities of T lymphocyte subsets in Behçet's disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. J Rheumatol 1992; 19: 742-6.
42. SZELES L, KERESZTES G, TOROCSIK D et al.: 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype, J Immunol 2009; 182: 2074-83.
43. GAUZZI MC, PURIFICATO C, DONATO K et al.: Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis, J Immunol 2005; 174: 270-6.
44. PEDERSEN AW, HOLMSTROM K, JENSEN SS et al.: Phenotypic and functional markers for 1 alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells, Clin Exp Immunol 2009; 157: 48-59.
45. PENNA G, AMUCHASTEGUI S, GIARRATANA N et al.: 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells, J Immunol 2001; 178: 145-53.